We studied product inhibition of the actin-activated ATPase of myosin subfragment-1 (S-i) from the three types of muscle tissue: skeletal, cardiac, and smooth. Increasing levels of [MgADP] in the 0-1-mM range caused significant inhibition of the actin-activated MgATPase activity of cardiac and gizzard but not skeletal muscle S-1. When total nucleotide concentration ([ATP]+ [ADP]) was kept constant at 1 mM, ATPase activity was inhibited by 50% at an ADP/ATP ratio of 6: 1 for cardiac S-1 and 3:1 for gizzard S-1. For skeletal S-1, however, even a 19:1 ratio did not cause 50%o inhibition of ATPase activity. To simplify the mathematical modeling of the sixstate model, it is usually assumed that the "on" rate of ATP to acto-S-1 is very rapid and that the "of' rate for the products of hydrolysis is not rate limiting for hydrolysis. Hence, there is no significant population of the states A-M or A-M-ADP during the steady-state hydrolysis of ATP. However, routine studies in our laboratory on the steady-state hydrolysis of ATP by acto-S-1 of cardiac and smooth muscle origin show that the actinactivated ATPase activity decreases with time as the reaction progresses. This is not due to the protein denaturing, because addition of ATP returns the rate toward normal. Skeletal S-1 shows a fall in rate when the substrate is virtually exhausted, but in the cardiac and smooth muscle systems, the rate falls at ATP concentrations normally considered to be saturating.
hydrolysis of ATP to ADP and inorganic phosphate (Pi) by the myosin ATPase. To gain an understanding of the actin-myosin interaction from a molecular standpoint, biochemists have turned to the biochemical kinetics of the actin-activated myosin ATPase activity, which is the in vitro correlate to contraction in vivo. Kinetic studies of the myosin ATPase activity of striated myosin have led to the development of a six-state kinetic model capable of accounting for the great majority of the available pre-steady-state and steady-state data' (see Figure la) , and recent physiological data also appear to support this model. [2] [3] [4] [5] In the six-state model, when actomyosin subfragment-1 (acto-S-1) is added to ATP, a rapid equilibrium (equilibrium binding constant K3, Figure la ) is established between actin-bound and actin-free subfragment-1 (S-1)-ATP complexes (i.e., M-ATP, where M is S-1; Figure la) . Hydrolysis of ATP then occurs on the surface of the myosin molecule in a^} ZI-ASX! * urn-w1 * u-Dw-u2
acto-S-1 found that ADP release was an order of magnitude slower in cardiac than in skeletal acto-S-1. 13 However, the "off" rate measured was still one The purpose of the present study was to evaluate ADP inhibition of the actin-activated ATPase of isolated myosin S-1 from the three distinct muscle tissues: cardiac, skeletal, and smooth. Smooth muscle S-1 has 1 ZD1111
traditionally been neglected as a kinetic model for smooth muscle myosin. However, we have observed recently that unphosphorylated gizzard S-1 has an actin- kATp, ATP "on" rate for acto-S-1; k ATp, ATP "offl' rate for acto-S-; kADp, ADP "on" rate for acto-S-1; k ADP, ADP "off' rate for acto-S-1.
These findings suggest that product inhibition is responsible for the fall in ATPase activity observed for cardiac and smooth muscle acto-S-1, and this was the impetus for the present studies. One possible model for product inhibition is that ADP is competing directly with ATP for the ATP binding site. Because of the data presented herewith, we favor this model as shown in Figure lb . Recently, there have been several reports of the effects of ADP on the actin-myosin interaction. In prior solution studies, ADP appeared to be a weak competitive inhibitor of the skeletal acto-S-1 MgATPase.6 Inhibition by ADP has also been reported for thiophosphorylated gizzard myosin using an in vitro motility assay.7 In cardiac muscle in vivo, hypoxic ventilation is accompanied by severe depression of cardiac function as well as a 50% increase in cardiac tissue ADP level. 8 In smooth muscle cells in vitro, ADP increases tension development and slows down crossbridge detachment.9-11 Also, the local concentration of ADP at the contractile apparatus may rise significantly during contraction in vivo. 8, 12 These findings suggest that ADP inhibition may be a physiologically important modulator of ATPase activity in cardiac and smooth muscle tissues. Prior kinetic studies on the rate of ADP release from bovine myosin
Materials and Methods

Proteins
Actin and skeletal myosin were prepared from rabbit skeletal muscle,16 and cardiac myosin was purified from swine cardiac tissue.' Smooth muscle myosin was isolated from frozen turkey gizzards.17-19 S-1 from skeletal and cardiac myosin was obtained by chymotryptic digestion' and from gizzard myosin by papain digestion. 19 We have also prepared gizzard S-1 by digestion with Staphylococcus aureus protease.20 The two gizzard subfragments differ in that the 20-kd regulatory light chain (LC20) and the 26-kd S-1 heavy chain fragment were cleaved by papain but not S. aureus protease, and this cleavage was associated with threefold to fourfold strengthened actin affinity for papain-digested S-1.14 However, there were no differences in the effects of ADP on papain versus S. aureus protease-digested S-1 kinetics. In the present study, we report the results for papain-digested S-1.
Chymotrypsin was obtained from Worthington Biochemical Corp., Freehold, N.J., and papain was obtained from Sigma Chemical Co., St. Louis, Mo.
Kinetic Studies
ATPase assays were performed as described previously by (y-_"P)ATP hydrolysis assay. constant k ATP directly and accurately (see Figure lb) , and this will be the subject of a subsequent report.
Mathematical Analysis of Inhibition Data
The data presented are shown to fit hyperbolic kinetics quite well, and it is of interest to use the hyperbolic fitting parameters to determine the ratio of [ (1) where VATP is the ATPase rate and F1 and F2 depend on the kinetic parameters in Figure 1, Hydrol,ysis Over Time Figure 2 shows the progressive inhibition of the actin-activated ATPase of cardiac S-1 as the hydrolysis of 1 mM ATP goes to completion. The ATPase activity was reduced by 20-30% of its initial value when 50% of the ATP had been hydrolyzed and by 50% when 80% of the ATP had been hydrolyzed. A concentration of 0.2 mM ATP would be near saturating for cardiac S-1 in the absence of added ADP,22 yet significant inhibition of ATPase activity was observed. The observed inhibition was unlikely to be secondary to a change in pH, since only a small drop in pH was observed in these experiments (approximately a 0.2-pH drop after 1 mM ATP was hydrolyzed to completion). However, measurement of pH in the presence of relatively concentrated protein solutions is difficult. Hence, we decided to control pH directly by hydrolyzing less than 0.1 mM ATP in each experiment, using the time course of complete hydrolysis of 1 mM ATP ( Figure 2) (1 free), 1 mM dithiothreitol, and 1 were varied, the reported concentrations were corrected for ATP split during the experiment. Figure 3 shows the normalized actin-activated ATPase for each protein, with the actin adjusted to a level that gave approximately half-maximal activation in the absence of added ADP (see Table 1 ). This provides a direct comparison of cardiac, smooth, and skeletal acto-S-1 at the KATPae of each protein tested, i.e., at the same level of activation by actin. These data indicate that for a given level of actin activation, ADP inhibits the ATPase of cardiac and smooth muscle S-1 to a much greater extent than it does skeletal muscle S-1. Both cardiac and gizzard S-1 exhibited significant ATPase inhibition at low levels of
[ADP] (' 0.5 mM), whereas skeletal S-1 did not. In addition, these data demonstrate that the inhibition observed in Figure 2 Figure 5 shows that 1.5 mM KP, had no significant effect compared with 2.4 mM KCI on the acto-S-1 ATPase activity for any of the three muscle types. Neither Vmax nor KATp.,e was affected by KPi. Thus, increasing [Pi] was not responsible for the inhibition observed in Figure 2 . Other studies using cardiac S-1 and KP1 concentrations up to 2.5 mM (requiring an Figure 6 shows plots at "low," "intermediate," and "high" actin concentrations for the three S-1 types. The choices of actin concentrations were made to see if actin had any significant effect on the inhibition observed. The data were analyzed using a least-squares hyperbolic fitting program.2' This procedure determined the values for F, and F2 from Equation 1 (see "Materials and Methods"). Table 2 lists these constants for the data in Figure 6 .
It is evident from Figure 6 that the data fit a hyperbolic plot reasonably well, strongly supporting the prediction of the models used (Figure 1) We were also able to estimate values for KmIKi from the data in Figure 6 (see "Materials and Methods").
The value of Km varies with the S-1 type as well as the actin concentration. To determine the ratio of these type at an actin concentration that caused halfmaximal activation in the absence ofadded ADP (see Table 1 ). These data are also included in Figure 6 without normalization. Conditions were as follows: 10 mM imidazole, 2 mM MgCI2 ( (2) (3) (4) (5) ,uM)"1 as well as an ADP association constant for cardiac acto-S-1 in vitro (4 1IM).13
Another point that needs to be examined is whether the new data presented here could have any effect on the prior interpretations of kinetic data with cardiac proteins from our laboratory. We do not believe this to be the case, because we were aware very early that the ATPase activity of cardiac acto-S-1 was initially linear and then appeared to slow down late in the reaction. Skeletal acto-S-1 also slowed down but not until 90+% of the ATP was split, whereas for cardiac S-1 it was clear that, unlike results obtained with skeletal proteins, the turbidity of cardiac acto-S-1 in the presence of ATP began to rise very slowly after approximately half of the ATP was split. Hence, all of our reported studies were carried out under conditions in which reasonable linearity was ensured, i.e., conditions in which less than 50% of the ATP was split and The latch model predicts a linear relation between shortening velocity and MLC phosphorylation. However, when comparing the relation between shortening velocity and MLC phosphorylation for various tissue types, there are variations that cannot be explained by the small observed differences in the inherent ATPase rates of the purified myosins.33. In addition, there are differences in the relation between shortening velocity and MLC phosphorylation in a given tissue when stimulated by different agonists.33 Again, these differences may be related to Ca2+-regulated thin-filament proteins, but ADP may be an additional or alternative modulator of the crossbridge cycling rate.
